| Autor: |
De Malglaive, Pauline, Groh, Matthieu, Lefèvre, Guillaume, Morati Hafsaoui, Chafika, Alexis, Magda, Hunault, Mathilde, Seneschal, Julien, Charlanne, Hilaire, Preudhomme, Claude, Bonnotte, Bernard, Kahn, Jean Emmanuel |
| Zdroj: |
Blood; November 2019, Vol. 134 Issue: 1, Number 1 Supplement 1 p2322-2322, 1p |
| Abstrakt: |
Background: Corticosteroids and imatinib are the first line treatment in hypereosinophilic syndromes (HES) according FIP1L1-PDGFRA (F/P) positivity. In HES unrelated to F/P, second line available treatment are historically interferon alpha (IFN-α) and hydroxyurea, while anti-interleukin-5 antibodies are currently investigated. Data concerning efficacy of IFN-αin HES are limited to small case series and one large international study with a short-term follow-up. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
